Glenmark Pharmaceuticals Inc., USA has made a statement regarding its imminent launch of a generic form of the widely used ADHD medication Adderall in the US market. The drug, containing mixed salts of a single-entity amphetamine, will be marketed in 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg strengths from May 2025.

Key Highlights

Bioequivalent to Adderall
Glenmark's drug product contains dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate, and amphetamine sulfate - equivalent to Teva Women's Health, Inc.'s reference-listed Adderall.

Addressing U.S. Shortage

• Glenmark is focused on filling the chronic U.S. shortage of ADHD drugs, a trend that has increasingly posed concerns to patients and clinicians alike.

• Marc Kikuchi, President & Business Head, North America, stated, "This is a very well-prescribed medicine. Glenmark is extremely pleased to contribute towards relieving the shortage with this upcoming launch."

Market Opportunity
Based on IQVIA sales data, the market for the Adderall tablet in the U.S. stood at about $421.7 million of annual sales as of the last 12 months ended February 2025.

Global Manufacturing Backbone
Glenmark Pharmaceuticals Ltd. has 11 manufacturing plants spread over four continents and markets in more than 80 countries, with a focus on cardiometabolic, respiratory, dermatology, and oncology segments.With this launch, Glenmark not only enters a space of high demand for therapy but also as a major player in filling exigent drug supply needs in the U.S. healthcare system. The generic Adderall tablets should make available affordable and timely treatment to narcolepsy and ADHD patients beginning May 2025.